Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
PHASE2CompletedINTERVENTIONAL
Enrollment
13
Participants
Timeline
Start Date
September 30, 2014
Primary Completion Date
October 31, 2016
Study Completion Date
November 30, 2016
Conditions
Lymphoma, T-Cell
Interventions
DRUG
MLN9708
Trial Locations (1)
48109
University of Michigan Hospital, Ann Arbor
All Listed Sponsors
lead
University of Michigan Rogel Cancer Center
OTHER
NCT02158975 - Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas | Biotech Hunter | Biotech Hunter